Bayer presented primary Phase II ARACOG trial results at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.
The head-to-head study met its primary endpoint.
NUBEQA (darolutamide) demonstrated significantly less cognitive decline compared to enzalutamide in advanced prostate cancer patients.
Patients treated with NUBEQA showed less impairment in executive function and working memory over a 24-week period.
The findings establish a clinical differentiator for NUBEQA in the treatment of advanced prostate cancer.
Bayer showcased 16 oncology abstracts at the conference to highlight its development pipeline.